Seer Reports Second Quarter 2025 Financial Results and Reiterates Full Year 2025 Outlook
Seer (Nasdaq: SEER), a life sciences company focused on proteomics, reported its Q2 2025 financial results with revenue of $4.1 million, representing a 32% year-over-year growth. The quarter was marked by the launch of their new high-throughput Proteograph ONE assay and SP200 automation instrument.
Key financial metrics include gross profit of $2.1 million with a 52% gross margin. Operating expenses decreased 21% to $22.6 million, while net loss improved to $19.4 million. The company maintains a strong balance sheet with $263.3 million in cash and investments. Seer reiterated its full-year 2025 revenue guidance of $17-18 million, projecting 24% growth at the midpoint.
Notable developments include a collaboration with Korea University for a 20,000-sample population-scale proteomics study focused on cancer diagnostics in young adults.
Seer (Nasdaq: SEER), un'azienda nel settore delle scienze della vita specializzata in proteomica, ha comunicato i risultati finanziari del secondo trimestre 2025 con un fatturato di 4,1 milioni di dollari, segnando una crescita del 32% rispetto all'anno precedente. Il trimestre è stato caratterizzato dal lancio del nuovo test Proteograph ONE ad alta produttività e dello strumento di automazione SP200.
I principali indicatori finanziari mostrano un utile lordo di 2,1 milioni di dollari con un margine lordo del 52%. Le spese operative sono diminuite del 21%, attestandosi a 22,6 milioni di dollari, mentre la perdita netta si è ridotta a 19,4 milioni di dollari. L'azienda mantiene una solida situazione patrimoniale con 263,3 milioni di dollari in liquidità e investimenti. Seer ha confermato la guidance per l'intero 2025 con un fatturato previsto tra 17 e 18 milioni di dollari, prevedendo una crescita del 24% al valore medio.
Tra gli sviluppi rilevanti, si segnala una collaborazione con la Korea University per uno studio proteomico su larga scala con 20.000 campioni, focalizzato sulla diagnosi del cancro nei giovani adulti.
Seer (Nasdaq: SEER), una empresa de ciencias de la vida enfocada en proteómica, reportó sus resultados financieros del segundo trimestre de 2025 con ingresos de 4.1 millones de dólares, lo que representa un crecimiento interanual del 32%. El trimestre estuvo marcado por el lanzamiento de su nuevo ensayo Proteograph ONE de alto rendimiento y el instrumento de automatización SP200.
Los principales indicadores financieros incluyen un beneficio bruto de 2.1 millones de dólares con un margen bruto del 52%. Los gastos operativos disminuyeron un 21% hasta 22.6 millones de dólares, mientras que la pérdida neta mejoró a 19.4 millones de dólares. La compañía mantiene un balance sólido con 263.3 millones de dólares en efectivo e inversiones. Seer reiteró su guía de ingresos para todo el año 2025 de 17-18 millones de dólares, proyectando un crecimiento del 24% en el punto medio.
Entre los desarrollos destacados se encuentra una colaboración con la Universidad de Corea para un estudio proteómico a escala poblacional con 20,000 muestras, centrado en el diagnóstico del cáncer en adultos jóvenes.
Seer (나스닥: SEER)는 단백질체학에 집중하는 생명과학 회사로, 2025년 2분기 재무 실적을 발표하며 매출 410만 달러를 기록해 전년 동기 대비 32% 성장을 보였습니다. 이번 분기는 새로운 고속 처리 Proteograph ONE 분석법과 SP200 자동화 장비의 출시가 특징이었습니다.
주요 재무 지표로는 210만 달러의 총이익과 52%의 총이익률이 포함됩니다. 영업비용은 21% 감소한 2,260만 달러였으며, 순손실은 1,940만 달러로 개선되었습니다. 회사는 2억 6,330만 달러의 현금 및 투자 자산을 보유하며 견고한 재무 상태를 유지하고 있습니다. Seer는 2025년 연간 매출 가이던스를 1,700만~1,800만 달러로 재확인하며 중간값 기준 24% 성장을 예상합니다.
주목할 만한 발전으로는 한국대학교와의 협력으로 20,000개 샘플 규모의 인구 기반 단백질체 연구가 진행 중이며, 이는 젊은 성인의 암 진단에 중점을 두고 있습니다.
Seer (Nasdaq : SEER), une entreprise des sciences de la vie spécialisée en protéomique, a publié ses résultats financiers du deuxième trimestre 2025 avec un chiffre d'affaires de 4,1 millions de dollars, représentant une croissance de 32 % sur un an. Le trimestre a été marqué par le lancement de leur nouveau test Proteograph ONE à haut débit et de l'instrument d'automatisation SP200.
Les principaux indicateurs financiers comprennent un bénéfice brut de 2,1 millions de dollars avec une marge brute de 52 %. Les dépenses d'exploitation ont diminué de 21 % pour atteindre 22,6 millions de dollars, tandis que la perte nette s'est améliorée à 19,4 millions de dollars. L'entreprise maintient un bilan solide avec 263,3 millions de dollars en liquidités et investissements. Seer a réitéré ses prévisions de chiffre d'affaires pour l'année 2025 entre 17 et 18 millions de dollars, projetant une croissance de 24 % au point médian.
Parmi les développements notables figure une collaboration avec l'Université de Corée pour une étude protéomique à l'échelle de la population avec 20 000 échantillons, axée sur le diagnostic du cancer chez les jeunes adultes.
Seer (Nasdaq: SEER), ein Life-Sciences-Unternehmen mit Fokus auf Proteomik, meldete seine Finanzergebnisse für das zweite Quartal 2025 mit Einnahmen von 4,1 Millionen US-Dollar, was einem Wachstum von 32 % im Jahresvergleich entspricht. Das Quartal war geprägt von der Einführung ihres neuen hochdurchsatzfähigen Proteograph ONE Assays und des SP200 Automatisierungsgeräts.
Wichtige Finanzkennzahlen umfassen einen Bruttogewinn von 2,1 Millionen US-Dollar bei einer Bruttomarge von 52 %. Die Betriebskosten sanken um 21 % auf 22,6 Millionen US-Dollar, während der Nettoverlust auf 19,4 Millionen US-Dollar verbessert wurde. Das Unternehmen verfügt über eine starke Bilanz mit 263,3 Millionen US-Dollar in bar und Investitionen. Seer bestätigte seine Umsatzprognose für das Gesamtjahr 2025 von 17-18 Millionen US-Dollar und erwartet beim Mittelwert ein Wachstum von 24 %.
Bemerkenswerte Entwicklungen umfassen eine Zusammenarbeit mit der Korea University für eine bevölkerungsweite Proteomikstudie mit 20.000 Proben, die sich auf die Krebsdiagnostik bei jungen Erwachsenen konzentriert.
- None.
- Continued operating losses of $19.4 million in Q2
- Macroeconomic pressures affecting customer base
- Revenue remains relatively small at $4.1 million despite growth
Insights
Seer's 32% revenue growth and new high-throughput product launches represent positive progress despite continued operating losses and early commercialization stage.
Seer reported
The company achieved a gross margin of
Seer's financial position remains relatively strong with approximately
The launch of the high-throughput Proteograph ONE assay and SP200 automation instrument represents a significant product expansion that enhances the platform's scalability and efficiency. These new offerings have already enabled a strategic collaboration with Korea University for a 20,000-sample population-scale proteomics study focused on AI-driven cancer diagnostics. This large-scale implementation validates the platform's capabilities for high-volume proteomics research.
Management has reiterated full-year 2025 revenue guidance of
Revenue grew
Launched new high-throughput Proteograph® ONE assay and SP200 automation instrument
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2025.
Recent Highlights
- Achieved revenue of
$4.1 million for the second quarter of 2025 - Launched new high-throughput Proteograph ONE assay and SP200 automation instrument, enabling previously unattainable scale and efficiency
- Announced a collaboration with Korea University to launch a 20,000-sample population-scale proteomics study utilizing the Proteograph ONE assay to develop AI-driven diagnostics for cancers in young adults
- Accelerated third-party validation through impactful data presentations and publications from key opinion leaders at recent conferences
- Ended the quarter with approximately
$263.3 million of cash, cash equivalents and investments
“Our team delivered a solid second quarter and achieved a pivotal milestone with the launches of our high-throughput Proteograph ONE assay and SP200 instrument, which significantly enhance the scalability and efficiency of our platform,” said Omid Farokhzad, Chair and CEO of Seer. “Seer was founded on the belief that we could transform the field of deep, unbiased proteomics. It’s incredibly rewarding to see that vision come to fruition, with our technology now powering multiple population-scale studies. I’m deeply proud of our team’s relentless focus on innovation and execution, even with continued macroeconomic pressures affecting our customer base.”
Second Quarter 2025 Financial Results
Revenue was
Gross profit was
Operating expenses were
Net loss was
Cash, cash equivalents and investments were approximately
2025 Guidance
Seer continues to expect full year 2025 revenue to be in the range of
Webcast Information
Seer will host a conference call to discuss the second quarter 2025 financial results on Wednesday, August 6, 2025 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph® Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges that conventional methods have failed to overcome. Traditional proteomic technologies have historically struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations for future results of operations and its financial position, business strategy, partnerships, adoption of our products and outlook for fiscal year 2025. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
| SEER, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product | $ | 2,726 | $ | 1,761 | $ | 5,616 | $ | 3,429 | ||||||||
| Service | 797 | 682 | 2,000 | 1,090 | ||||||||||||
| Related party | 409 | 583 | 461 | 1,537 | ||||||||||||
| Other | 119 | 46 | 179 | 82 | ||||||||||||
| Total revenue | 4,051 | 3,072 | 8,256 | 6,138 | ||||||||||||
| Cost of revenue: | ||||||||||||||||
| Product | 1,167 | 701 | 2,541 | 1,692 | ||||||||||||
| Service | 395 | 362 | 926 | 631 | ||||||||||||
| Related party | 69 | 156 | 139 | 468 | ||||||||||||
| Other | 309 | 122 | 478 | 255 | ||||||||||||
| Total cost of revenue | 1,940 | 1,341 | 4,084 | 3,046 | ||||||||||||
| Gross profit | 2,111 | 1,731 | 4,172 | 3,092 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 11,985 | 12,734 | 23,335 | 24,999 | ||||||||||||
| Selling, general and administrative | 10,656 | 16,093 | 22,098 | 30,381 | ||||||||||||
| Total operating expenses | 22,641 | 28,827 | 45,433 | 55,380 | ||||||||||||
| Loss from operations | (20,530 | ) | (27,096 | ) | (41,261 | ) | (52,288 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 2,992 | 4,433 | 6,209 | 9,019 | ||||||||||||
| Loss on equity method investment | (1,841 | ) | — | (3,416 | ) | — | ||||||||||
| Other income (expense) | 3 | (187 | ) | (755 | ) | (260 | ) | |||||||||
| Total other income | 1,154 | 4,246 | 2,038 | 8,759 | ||||||||||||
| Loss before provision for income taxes | (19,376 | ) | (22,850 | ) | (39,223 | ) | (43,529 | ) | ||||||||
| Provision for income taxes | 48 | — | 149 | — | ||||||||||||
| Net loss | $ | (19,424 | ) | $ | (22,850 | ) | $ | (39,372 | ) | $ | (43,529 | ) | ||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized gain (loss) on available-for-sale securities | 2 | (105 | ) | 171 | (434 | ) | ||||||||||
| Comprehensive loss | $ | (19,422 | ) | $ | (22,955 | ) | $ | (39,201 | ) | $ | (43,963 | ) | ||||
| Net loss per share attributable to Class A and Class B common stockholders, basic and diluted | $ | (0.33 | ) | $ | (0.35 | ) | $ | (0.67 | ) | $ | (0.67 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted | 58,087,565 | 64,576,399 | 58,744,490 | 64,581,228 | ||||||||||||
| SEER, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 37,931 | $ | 40,753 | ||||
| Short-term investments | 171,895 | 195,657 | ||||||
| Accounts receivable, net | 3,905 | 3,997 | ||||||
| Related party receivables | 409 | 379 | ||||||
| Other receivables | 1,400 | 1,853 | ||||||
| Inventory | 7,512 | 7,436 | ||||||
| Prepaid expenses and other current assets | 2,586 | 3,248 | ||||||
| Total current assets | 225,638 | 253,323 | ||||||
| Long-term investments | 53,426 | 63,103 | ||||||
| Operating lease right-of-use assets | 21,657 | 22,791 | ||||||
| Property and equipment, net | 16,496 | 18,575 | ||||||
| Restricted cash | 524 | 524 | ||||||
| Other assets | 4,746 | 8,281 | ||||||
| Total assets | $ | 322,487 | $ | 366,597 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,672 | $ | 4,621 | ||||
| Accrued expenses | 6,106 | 7,937 | ||||||
| Deferred revenue | 540 | 408 | ||||||
| Operating lease liabilities, current | 2,441 | 2,312 | ||||||
| Other current liabilities | 26 | 50 | ||||||
| Total current liabilities | 11,785 | 15,328 | ||||||
| Operating lease liabilities, net of current portion | 22,390 | 23,652 | ||||||
| Other noncurrent liabilities | 20 | 48 | ||||||
| Total liabilities | 34,195 | 39,028 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Class A common stock, | 1 | 1 | ||||||
| Class B common stock, | — | — | ||||||
| Additional paid-in capital | 719,728 | 719,804 | ||||||
| Accumulated other comprehensive gain | 307 | 136 | ||||||
| Accumulated deficit | (431,744 | ) | (392,372 | ) | ||||
| Total stockholders’ equity | 288,292 | 327,569 | ||||||
| Total liabilities and stockholders’ equity | $ | 322,487 | $ | 366,597 | ||||
FAQ
What was Seer's (SEER) revenue growth in Q2 2025?
How much cash does Seer (SEER) have as of Q2 2025?
What is Seer's (SEER) revenue guidance for full year 2025?
What new products did Seer (SEER) launch in Q2 2025?
What was Seer's (SEER) net loss in Q2 2025?
